MedImmune, Inserm and Inserm Transfert Renew Strategic Research Partnership

July 21, 2017, Gaithersburg, Md. and Paris – MedImmune, the global biologics research and development arm of AstraZeneca, and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), today announced the renewal of a collaboration to advance research across a range of therapeutic areas including oncology, respiratory, inflammation, and autoimmune diseases. This collaboration, launched in 2011, has been renewed for the second time, enabling the partnership to extend its work for a total of nine years. The new three-year term is intended to build upon key ongoing research in translational biology and new disease mechanisms.

Since the partnership’s inception, the collaborative research has yielded eighteen scientific publications in peer reviewed journals, as well as eight patent applications. These include several important advances and publications on immuno-oncology and the tumor microenvironment.  

Pascale Augé, Chairman of the Executive Management Board of Inserm Transfert said, “This alliance is part of our long-term strategic vision, and—leveraging our collaborative relationship with MedImmune—we are excited to continue advancing cutting edge science from our laboratories. The strength of our projects, where academic and industrial excellence meet, enables us to allow for the best innovation at the highest international standards.”

Yves Levy, Inserm’s Chief Executive Officer, said “Inserm’s leading global rankings in pharmaceutical and biotechnology patent applications is thanks to partnerships like this one with MedImmune (1st in Europe in the pharmaceutical sector; 2nd in Europe in the Biotechnology field). I’m delighted that this ‘win-win’ partnership has been renewed with a commitment to improving human health.” 

“MedImmune is pleased to continue its partnership with a premier organization such as Inserm to pursue translational science that can serve as the basis of new discovery for patients in need,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “This relationship exemplifies our commitment to collaborations, which are so critical to creating new avenues for innovative ideas and going where the best science lives.”

Via decision-making governance by a Joint Steering Committee, MedImmune will continue to fund projects to be executed with Inserm for both pre-clinical and clinical research, and will execute other activities to help identify promising approaches to advance drug candidates for patients with unmet medical needs.


About MedImmune 
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit

About Inserm
Founded in 1964, the French National Institute of Health and Medical research (Inserm) is a public science and technology institute, jointly supervised by the French Ministry of National Education, Higher Education and Research and the Ministry of Social Affairs, Health and women's Rights. Inserm is the only French public research institute to focus entirely on human health with nearly 15 000 researchers, engineers, technicians, post-doctoral students and more than 300 laboratories. The mission of its scientists is to study all diseases, from the most common to the rarest. Inserm is a member of Aviesan, the French National Alliance for Life Sciences and Health founded in 2009. Other founding members of Aviesan: CEA, CNRS, CHRU, CPU, INRA, INRIA, Institut Pasteur, IRD.

About Inserm Transfert
Founded in 2000, InsermTransfert SA is the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), dedicated to technology transfer (from invention disclosure to industrial partnership and spin off). Inserm Transfert also manages European and International research projects, supports large scale projects in epidemiology and public health.  Inserm Transfert runs an internal proof of concept fund.  The company also supports entrepreneurs in the biotech sector, in partnership with Inserm Transfert Initiative.